Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C

Updated: Dec 15, 2020

Wuerth K, Magel T, Conway B. Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C. Future Virology. 2019; 14(11).


Full text: https://doi.org/10.2217/fvl-2019-0104


Advances in hepatitis C virus (HCV) treatment led to the development of highly effective all oral direct acting antiviral regimens. The combination of sofosbuvir and velpatasvir (SOF/VEL), two agents acting synergistically at different stages in the viral life cycle, has been evaluated in a broad range of clinical trials supporting its efficacy in complex and diverse patient populations. Following regulatory approval in 2016, SOF/VEL has been widely used as a safe, effective pangenotypic regimen in clinical practice. In this review, we will discuss the current preclinical, clinical and real-world data on SOF/VEL.

Recent Posts

See All

© 2020 by Vancouver Infectious Diseases Centre. 

logo%20png_edited.png